COMPASS Pathways plc
CMPSHealthcare|Biotechnology|GB
$8.61
+0.80 (+10.24%)
DCF Value
$1.38
Tangible Book / Share
$1.02
Cash / Share
$3.20
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05711940 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD | Treatment Resistant Depression | P3 | Active | 572 | RCT, Double-blind | Psilocybin |
| NCT07570654 Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | PTSD - Post Traumatic Stress Disorder, PTSD | P2P3 | Recruiting | 300 | RCT, Double-blind | COMP360 psilocybin |
| NCT06247839 The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder | Major Depressive Disorder | P3 | Recruiting | 20 | Open-label | Psilocybin |
| NCT05733546 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | Major Depressive Disorder | P2 | Active | 102 | RCT, Double-blind | Psilocybin |
| NCT05624268 Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD | Treatment Resistant Depression | P3 | Completed | 258 | RCT, Double-blind | Psilocybin |
| NCT05312151 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Post Traumatic Stress Disorder | P2 | Completed | 22 | Open-label | Psilocybin |
| NCT05481736 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | Anorexia Nervosa | P2 | Completed | 32 | RCT, Double-blind | Psilocybin |
| NCT03775200 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression | Treatment Resistant Depression | P2 | Completed | 233 | RCT, Double-blind | Psilocybin |
| NCT04656301 Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder | Body Dysmorphic Disorders | P2 | Completed | 12 | Open-label | Psilocybin |
| NCT05220410 The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | Treatment Resistant Depression, Suicidal Ideation | P2 | Completed | 20 | Open-label | Psilocybin |
| NCT05381974 The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD | Treatment-Resistant Major Depressive Disorder | P2 | Withdrawn | — | Open-label | Psilocybin |
| NCT04739865 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression | Treatment Resistant Depression | P2 | Completed | 19 | Open-label | Psilocybin |
| NCT04433845 The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | Treatment Resistant Depression | P2 | Unknown | 15 | Open-label | Psilocybin |
| NCT04661514 Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | Anorexia Nervosa | P2 | Completed | 16 | Open-label | Psilocybin |
| NCT04433858 An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) | Treatment Resistant Depression | P2 | Unknown | 27 | Open-label | Psilocybin |
| NCT04519957 Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) | Treatment Resistant Depression | Completed | 66 | — | — |